- Home
- BLFS vs EYPT Comparison
BLFS vs EYPT Comparison
Compare BLFS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | EYPT |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BLFS | EYPT |
|---|---|---|
| Price | $28.67 | $13.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $32.00 | $31.80 |
| AVG Volume (30 Days) | 784.5K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | $7,539,000.00 |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | $3,115.57 |
| P/E Ratio | $1,375.00 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $8.96 |
| 52 Week High | $29.57 | $19.11 |
Technical Indicators
Market Signals| Indicator | BLFS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 54.50 |
| Support Level | $23.60 | $13.61 |
| Resistance Level | $28.90 | $14.82 |
| Average True Range (ATR) | 1.47 | 0.80 |
| MACD | -0.04 | 0.18 |
| Stochastic Oscillator | 71.75 | 64.85 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.